Recombinant human factor VIII (rFVIII), a multidomain glycoprotein is used in replacement therapy for treatment of hemophilia A. Unfortunately, 15%-30% of the treated patients develop inhibitory antibodies. The pathogenesis of antibody development is not completely understood. The presence of aggreg
✦ LIBER ✦
Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice
✍ Scribed by K. ØVLISEN; A. T. KRISTENSEN; L. A. VALENTINO; N. HAKOBYAN; J. INGERSLEV; M. TRANHOLM
- Book ID
- 109152512
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 240 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1538-7933
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Influence of aggregation on immunogenici
✍
Vivek S. Purohit; C. Russell Middaugh; Sathyamangalam V. Balasubramanian
📂
Article
📅
2006
🏛
John Wiley and Sons
🌐
English
⚖ 221 KB
Effect of route of administration of hum
✍
Aaron Peng; Puneet Gaitonde; Matthew P. Kosloski; Razvan D. Miclea; Prashant Var
📂
Article
📅
2009
🏛
John Wiley and Sons
🌐
English
⚖ 115 KB
Factor VIII is a multi-domain glycoprotein and is an essential cofactor in the blood coagulation cascade. Its deficiency or dysfunction causes Hemophilia A, a bleeding disorder. Replacement using exogenous recombinant Factor VIII (FVIII) is the first line of therapy for Hemophilia A. Immunogenicity,
Effect of recombinant factor VIIa varian
✍
D. F. BROPHY; E. J. MARTIN; M. E. NOLTE; J. G. KUHN; M. E. CARR JR
📂
Article
📅
2007
🏛
John Wiley and Sons
🌐
English
⚖ 648 KB
Effects of factor VIII inhibitor bypassi
✍
T. LIVNAT; U. MARTINOWITZ; A. ZIVELIN; U. SELIGSOHN
📂
Article
📅
2008
🏛
John Wiley and Sons
🌐
English
⚖ 219 KB
The effect of platelets on fibrin gel st
✍
S. HE; G. JACOBSSON EKMAN; U. HEDNER
📂
Article
📅
2005
🏛
John Wiley and Sons
🌐
English
⚖ 432 KB